We believe that CCR2 expression by CCR2+HSCs is maintained until the cells cross the blood-brain barrier, but is then either downregulated or shed within the tumor microenvironment once they have differentiated into antigen presenting cells. This evidence concerns the gene CCR2 and neoplasm.